Shares of Calithera Biosciences Inc (NASDAQ:CALA) gapped up prior to trading on Tuesday . The stock had previously closed at $8.70, but opened at $8.10. Calithera Biosciences shares last traded at $8.10, with a volume of 3522700 shares traded.
Several analysts have issued reports on CALA shares. Citigroup upgraded shares of Calithera Biosciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $6.95 to $14.00 in a research report on Friday. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Monday, November 6th. ValuEngine lowered shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, BidaskClub upgraded shares of Calithera Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, December 22nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $16.67.
The stock has a market cap of $282.04, a PE ratio of -8.18 and a beta of 2.56.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in Calithera Biosciences by 37.3% in the 4th quarter. BlackRock Inc. now owns 2,886,275 shares of the biotechnology company’s stock worth $24,099,000 after purchasing an additional 784,816 shares during the last quarter. Millennium Management LLC grew its position in Calithera Biosciences by 198.6% in the 4th quarter. Millennium Management LLC now owns 1,439,573 shares of the biotechnology company’s stock worth $12,020,000 after purchasing an additional 957,437 shares during the last quarter. State Street Corp boosted its position in shares of Calithera Biosciences by 5,802.1% during the 2nd quarter. State Street Corp now owns 1,304,375 shares of the biotechnology company’s stock valued at $19,370,000 after acquiring an additional 1,282,275 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Calithera Biosciences by 29.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock valued at $17,813,000 after acquiring an additional 274,510 shares in the last quarter. Finally, Ascend Capital LLC boosted its position in shares of Calithera Biosciences by 5.4% during the 4th quarter. Ascend Capital LLC now owns 693,801 shares of the biotechnology company’s stock valued at $5,792,000 after acquiring an additional 35,606 shares in the last quarter. Institutional investors own 73.64% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Calithera Biosciences (CALA) Shares Gap Up to $8.10” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/20/calithera-biosciences-cala-shares-gap-up-to-8-10.html.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.